Related Experiment Video
Updated: Nov 21, 2025
09:36
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
Published on: June 28, 2019
10.3K
Progressive Supranuclear Palsy and Corticobasal Degeneration
David G Coughlin1, Dennis W Dickson2, Keith A Josephs3
1UC San Diego, Department of Neurosciences, La Jolla, CA, USA.
Advances in Experimental Medicine and Biology
|January 12, 2021
Summary
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are 4R tau protein disorders. Recognizing diverse clinical signs is key for accurate diagnosis and future therapeutic trials.
Area of Science:
- Neuroscience
- Neuropathology
- Neurodegenerative Diseases
Background:
- Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are distinct neurodegenerative tauopathies.
- Both conditions feature neuronal and glial lesions primarily composed of 4R tau protein.
- Pathological overlap exists, but differences in lesion distribution, morphology, and comorbid pathology distinguish PSP and CBD.
Purpose of the Study:
- To highlight the phenotypic diversity in PSP and CBD.
- To emphasize the impact of phenotypic diversity on antemortem diagnostic accuracy.
- To discuss current and future management strategies for PSP and CBD.
Main Methods:
- Review of neuropathological features of PSP and CBD.
- Analysis of clinical manifestations and diagnostic challenges.
- Evaluation of current treatment standards and future therapeutic directions.
Main Results:
- PSP and CBD exhibit a wide spectrum of clinical presentations affecting movement and cognition.
- Diagnostic accuracy is high for typical PSP (Richardson syndrome) but low for characteristic CBD (corticobasal syndrome).
- Molecular and imaging biomarkers are needed to improve antemortem diagnosis.
Conclusions:
- Recognizing phenotypic variability is crucial for improving antemortem diagnosis of PSP and CBD.
- Multidisciplinary symptomatic and supportive care is the current standard.
- Experimental therapeutic trials are essential for future disease modification.
Related Concept Videos
01:15Parkinson's Disease: Overview
1.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
01:24Parkinson's Disease: Treatment
762
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
762
01:37Neural Regulation
41.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
41.9K
01:26Alzheimer's Disease: Overview
1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
01:24Prosopagnosia
541
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
541
01:11Direct Motor Pathways
3.4K
The direct motor pathways, also known as the pyramidal tracts, are a group of neural pathways that originate in the brain and descend through the spinal cord. They control the voluntary movement of the body. There are two major direct motor pathways: the corticospinal and the corticobulbar tracts.
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...
3.4K